Alzheimer's Disease Clinical Trials in Boston, MA

56 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	<1 mi
Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)	—	VA Office of Research and Development	<1 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	<1 mi
Triage Survey for Neurology Research Eligibility	—	Adams Clinical	<1 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)	—	University of Southern California	<1 mi
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)	Phase 1/2	AC Immune SA	<1 mi
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease	Phase 2	Brigham and Women's Hospital	<1 mi
Gamma-Music Based Intervention for Mild Alzheimer's Disease	N/A	Northeastern University	<1 mi
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease	N/A	Massachusetts General Hospital	<1 mi
Cognitive Neurology Unit Clinical Registry	—	Beth Israel Deaconess Medical Center	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)	—	University of Pennsylvania	<1 mi
A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population	—	Indivi AG	<1 mi
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia	N/A	Hebrew SeniorLife	<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	<1 mi
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease	Phase 2	Lighthouse Pharmaceuticals, Inc.	<1 mi
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases	Phase 1/2	Brigham and Women's Hospital	<1 mi
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease	Early 1	Massachusetts General Hospital	<1 mi
Dominantly Inherited Alzheimer Network (DIAN)	—	Washington University School of Medicine	<1 mi
Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0	N/A	Hebrew SeniorLife	<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia	Phase 2	Intra-Cellular Therapies, Inc.	<1 mi
Assess Fibrin in Brains With AD/ADRD	Phase 1/2	Massachusetts General Hospital	<1 mi
Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation	N/A	Boston University Charles River Campus	<1 mi
TMS for Cognitive Decline in Aging and Preclinical AD	N/A	Massachusetts General Hospital	<1 mi
Mindfulness for Cognition in Early-stage Alzheimer's Disease	N/A	VA Boston Healthcare System	<1 mi
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD	—	Massachusetts General Hospital	<1 mi
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology	Phase 2	Massachusetts General Hospital	<1 mi
Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease	N/A	Boston University Charles River Campus	<1 mi
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	Phase 1	Eli Lilly and Company	1 mi
Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease	N/A	Massachusetts General Hospital	1 mi
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	Phase 2	Eli Lilly and Company	1 mi
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy	N/A	Massachusetts Institute of Technology	3 mi
Gamma Frequency Stimulation in Individuals With Down Syndrome	N/A	Massachusetts Institute of Technology	3 mi
Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)	Phase 2	Massachusetts Institute of Technology	3 mi
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome	N/A	Hebrew SeniorLife	6 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	6 mi
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease	Phase 1/2	AbbVie	6 mi
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside	—	Mclean Hospital	7 mi
The BRAIN App (Phase 2 SBIR)	N/A	Hopeful Aging	8 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	8 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Phase 3	Bristol-Myers Squibb	8 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	8 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)	Phase 3	Bristol-Myers Squibb	8 mi
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).	Phase 3	Eli Lilly and Company	8 mi
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Lantheus Biosciences Ltd.	11 mi
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease	Phase 2	Novartis Pharmaceuticals	26 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	39 mi
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type	Phase 2	Teikoku Pharma USA, Inc.	39 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia	—	GAP Innovations, PBC	41 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	41 mi
Clinical Trial on Agitation in Alzheimer's Dementia	Phase 2	IGC Pharma, LLC	41 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	41 mi
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD	Phase 1	Butler Hospital	41 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	41 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.